CHRS Stock Overview
A biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Coherus BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.10 |
| 52 Week High | US$3.70 |
| 52 Week Low | US$0.66 |
| Beta | 0.69 |
| 11 Month Change | 27.70% |
| 3 Month Change | -20.86% |
| 1 Year Change | -45.54% |
| 33 Year Change | -94.19% |
| 5 Year Change | -94.00% |
| Change since IPO | -91.28% |
Recent News & Updates
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Recent updates
Investors Don't See Light At End Of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Tunnel And Push Stock Down 30%
Nov 06Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27Shareholder Returns
| CHRS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 42.4% | -6.5% | -1.0% |
| 1Y | -45.5% | 14.6% | 30.3% |
Return vs Industry: CHRS underperformed the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: CHRS underperformed the US Market which returned 30.3% over the past year.
Price Volatility
| CHRS volatility | |
|---|---|
| CHRS Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CHRS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CHRS's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 235 | Denny Lanfear | www.coherus.com |
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME.
Coherus BioSciences, Inc. Fundamentals Summary
| CHRS fundamental statistics | |
|---|---|
| Market cap | US$126.73m |
| Earnings (TTM) | -US$450.00k |
| Revenue (TTM) | US$304.34m |
0.4x
P/S Ratio-281.6x
P/E RatioIs CHRS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CHRS income statement (TTM) | |
|---|---|
| Revenue | US$304.34m |
| Cost of Revenue | US$168.26m |
| Gross Profit | US$136.08m |
| Other Expenses | US$136.53m |
| Earnings | -US$450.00k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0039 |
| Gross Margin | 44.71% |
| Net Profit Margin | -0.15% |
| Debt/Equity Ratio | -300.7% |
How did CHRS perform over the long term?
See historical performance and comparison